Biodexa’s MTX110 Shows Promise in Brain Cancer Study

Biodexa Pharmaceuticals (BDRX) has released an update.

Biodexa Pharmaceuticals reports promising interim results in their Phase 1 study of MTX110 for treating recurrent glioblastoma, showing favorable overall survival rates compared to standard treatments. The data also builds on previous positive outcomes from two Phase 1 studies in diffuse midline glioma, indicating the potential of MTX110, which is delivered directly to the tumor, in treating aggressive brain cancers.

For further insights into BDRX stock, check out TipRanks’ Stock Analysis page.